Results 51 to 60 of about 11,830 (209)

Clinical predictors of thiopurine-related adverse events in Crohn's disease [PDF]

open access: yes, 2015
AIM: To determine the incidence and predictors of thiopurine-related adverse events.METHODS: Subjects with Crohn's disease who were followed in the Alberta Inflammatory Bowel Disease Consortium patient database registry were identified.
Ghosh, Subrata   +8 more
core   +1 more source

Effect of developmental changes on pharmacokinetics of drugs used in the treatment of infant acute lymphoblastic leukaemia—A comprehensive review

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
While the event‐free survival (EFS) of children treated for acute lymphoblastic leukaemia (ALL) has improved greatly in the last decades, the EFS for patients diagnosed with ALL before the age of one is still under 50%. This outcome further decreases when infants have a rearrangement in the gene encoding histone‐lysine N‐methyltransferase 2A (KMT2A ...
Tirsa de Kluis   +5 more
wiley   +1 more source

NUDT15, FTO, and RUNX1 genetic variants and thiopurine intolerance among Japanese patients with inflammatory bowel diseases

open access: yesIntestinal Research, 2017
Background/Aims: Recent genome-wide analyses have provided strong evidence concerning adverse events caused by thiopurine drugs such as azathioprine (AZA) and 6-mercaptopurine.
Toshiyuki Sato   +13 more
doaj   +1 more source

Precision medicine in paediatrics: Progress and priorities

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Precision medicine is revolutionizing personalized healthcare, advancing both diagnostics and therapeutics at an unprecedented pace. Reviewing the paediatric applications of pharmacometrics, pharmacogenomics and advanced therapy medicinal products highlights not only the relevance of these exciting innovations to frontline care but also the significant
Nicola Husain   +3 more
wiley   +1 more source

The Utility of Thiopurine Methyltransferase Enzyme Testing in Inflammatory Bowel Disease

open access: yesCanadian Journal of Gastroenterology, 2013
OBJECTIVE: To assess the levels of red blood cell thiopurine methyltransferase (TPMT) in subjects with inflammatory bowel disease (IBD) and to determine how these levels impacted thiopurine dosing and leukopenia over the first six months of therapy.
Laura Chisick   +2 more
doaj   +1 more source

Clinical relevance of pharmacogenomic information for improving prescribing practices in acutely admitted older medical patients

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Safe prescribing and effective medication review during acute hospitalization depends on accurate information about liver and kidney function because these organs are responsible for the elimination of most medications. While estimates for kidney function are widely used, comparable markers of hepatic drug‐metabolizing capacity are not routinely ...
Louise Westberg Strejby Christensen   +17 more
wiley   +1 more source

N6‐Methyladenosine in Inflammatory Bowel Disease: An Emerging Regulator of Pathogenesis and a Novel Therapeutic Frontier

open access: yesiMetaMed, EarlyView.
Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the intestine associated with an imbalance in intestinal homeostasis. m6A‐modifying enzymes, consisting of m6A writers, erasers and readers, plays a pivotal role in the pathogenesis and progression of IBD by affecting four intestinal barriers, including the intestinal mechanical ...
Jiaxian Guo   +4 more
wiley   +1 more source

TPMT and NUDT15 polymorphisms in thiopurine induced leucopenia in inflammatory bowel disease: a prospective study from India

open access: yesBMC Gastroenterology, 2021
Background Polymorphisms in thiopurine methyltransferase (TPMT) and Nudix hydrolase-15 (NUDT15) have been implicated as the predominant cause of thiopurine induced leukopenia in the Western countries and East Asia respectively.
Narinder Grover   +9 more
doaj   +1 more source

Interplay between IL6 and CRIM1 in thiopurine intolerance due to hematological toxicity in leukemic patients with wild-type NUDT15 and TPMT

open access: yesScientific Reports, 2021
NUDT15 and TPMT variants are strong genetic determinants of thiopurine-induced hematological toxicity. Despite the impact of homozygous CRIM1 on thiopurine toxicity, several patients with wild-type NUDT15, TPMT, and CRIM1 experience thiopurine toxicity ...
Hyery Kim   +14 more
doaj   +1 more source

NUDT15 Pharmacogenetics in Acute Lymphoblastic Leukemia: Synthesizing Progress for Personalized Thiopurine Therapy

open access: yesMedical Sciences
The management of acute lymphoblastic leukemia (ALL), the most common pediatric malignancy, critically relies on thiopurine therapy, such as 6-mercaptopurine (6-MP), during the maintenance phase. However, significant inter-individual response variety and
Isfahan Shah Lubis   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy